DDInter1836 DDInter915
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Torasemide {u} (Compound) causes {v} (Side Effect) Atrial fibrillation
Atrial fibrillation {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Torasemide {u} (Compound) upregulates {v} (Gene) PAK1
PAK1 {u} (Gene) is upregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Torasemide {u} (Compound) downregulates {v} (Gene) BASP1
BASP1 {u} (Gene) is downregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Torasemide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Torasemide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Torasemide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Torasemide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Torasemide {u} (Compound) treats {v} (Disease) hypertension
hypertension {u} (Disease) is associated with {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Torasemide {u} (Compound) downregulates {v} (Gene) STUB1
STUB1 {u} (Gene) interacts with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Torasemide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Irinotecan {u} (Compound) upregulates {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Indacaterol
Torasemide (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Indacaterol (Compound)
Torasemide (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Torasemide (Compound) downregulates BASP1 (Gene) and BASP1 (Gene) is downregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Indacaterol (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)
Torasemide (Compound) treats hypertension (Disease) and hypertension (Disease) is associated with ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Torasemide (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) interacts with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan (Compound) upregulates ADRB2 (Gene) and ADRB2 (Gene) is bound by Indacaterol (Compound)